I agree, was very positive. I took some notes; NTRP discussion started at minute 41.
Bryostatin, NTRP’s drug, can you talk about the mechanism there; previous phase 2 showed a very strong signal in moderate? Response - among the more encouraging data that I’ve seen, the body of science around it is very strong; have identified a subgroup in previous phase 1 and 2 studies, specifically patients who were not on memantine who benefitted strongly – confirmatory study has been underway and are at a stage where they may in the next few months be presenting that data; if it is confirmatory, it will be very exciting because it will be a new and very different mechanism that might be very useful in our population; they are targeting a population that has a big unmet need, moderate to severe; most are targeting early stage disease; this is one of the few targeting late stage; looking forward to seeing that data and hopefully will show beneficial effects;
FU question on Bryostatin – in the prior phase 2 trial, Bryostatin show a 6pt over baseline and an 8 over placebo; Have you seen anything like that in any other studies in recent years; I have not, that’s the best effect I’ve seen in any drug or any class… 15-16 showed improvement. Encouraging signal; the fact tat they could get patients not on memantine was very useful; didn’t see the actual data.
News 
Market Data 
Discover 
